Corporate News

Change of preliminary results date

31 August 2022

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition products, announces that the publication of the preliminary results for the year ended 31 March 2022 will be further delayed as the Company and its auditors require additional time to finalise the accounting treatment and disclosures relating to the recent sale of the CD4 business and for the Company’s auditors to complete their transactional testing.  This work is now expected to be completed in mid-September. 


The delay to publication now means that the AGM planned for 5 October 2022 will no longer take place and a revised date will be communicated shortly.




Omega Diagnostics Group PLC
Jag Grewal Chief Executive Officervia Walbrook PR
Chris Lea, Chief Financial Officer  
finnCap LtdTel: 020 7220 0500
Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance)  
Alice Lane/ Harriet Ward (ECM)  
Walbrook PR Limited Tel: 020 7933 8780 or [email protected]
Paul McManus Mob: 07980 541 893
Lianne Applegarth Mob: 07584 391 303
Sam Allen Mob: 07502 558 258


About Omega Diagnostics Group PLC  

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 70 countries and is now focused on the health and nutrition sector. 

Sign up for Investor Alerts